Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUVE-X long-term baricitinib study in pediatric juvenile idiopathic arthritis
2023-506131-15-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in juvenile idiopathic arthritis (JIA), sponsored by Eli Lilly and Company. Planned start Sep 2019; status: authorised.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2023-506131-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506131-15-00.